Last data update: Apr 18, 2025. (Total: 49119 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Relan P[original query] |
---|
Injection drug use-associated candidemia: Incidence, clinical features, and outcomes, east Tennessee, 2014-2018
Rossow JA , Gharpure R , Brennan J , Relan P , Williams SR , Vallabhaneni S , Jackson BR , Graber CR , Hillis SR , Schaffner W , Dunn JR , Jones TF . J Infect Dis 2020 222 S442-s450 BACKGROUND: Injection drug use (IDU) is an established but uncommon risk factor for candidemia. Surveillance for candidemia is conducted in East Tennessee, an area heavily impacted by the opioid crisis and IDU. We evaluated IDU-associated candidemia to characterize the epidemiology and estimate the burden. METHODS: We assessed the proportion of candidemia cases related to IDU during January 1, 2014-September 30, 2018, estimated candidemia incidence in the overall population and among persons who inject drugs (PWID), and reviewed medical records to compare clinical features and outcomes among IDU-associated and non-IDU candidemia cases. RESULTS: The proportion of IDU-associated candidemia cases in East Tennessee increased from 6.1% in 2014 to 14.5% in 2018. Overall candidemia incidence in East Tennessee was 13.5/100 000, and incidence among PWID was 402-1895/100 000. Injection drug use-associated cases were younger (median age, 34.5 vs 60 years) and more frequently had endocarditis (39% vs 3%). All-cause 30-day mortality was 8% among IDU-associated cases versus 25% among non-IDU cases. CONCLUSIONS: A growing proportion of candidemia in East Tennessee is associated with IDU, posing an additional burden from the opioid crisis. The lower mortality among IDU-associated cases likely reflects in part the younger demographic; however, Candida endocarditis seen among approximately 40% underscores the seriousness of the infection and need for prevention. |
Notes from the Field: Cholera outbreak - Zimbabwe, September 2018-March 2019
Winstead A , Strysko J , Relan P , Conners EE , Martinsen AL , Lopez V , Arons M , Masunda KPE , Mukeredzi I , Manyara J , Duri C , Mashe T , Phiri I , Poncin M , Sreenivasan N , Aubert RD , Fuller L , Balachandra S , Mintz E , Manangazira P . MMWR Morb Mortal Wkly Rep 2020 69 (17) 527-528 During September 5–6, 2018, a total of 52 patients in Harare, Zimbabwe, were hospitalized with suspected cholera, an acute bacterial infection characterized by watery diarrhea. Rapid diagnostic testing was positive for Vibrio cholerae O1, and on September 6, Zimbabwe’s Ministry of Health and Child Care (MOHCC) declared an outbreak of cholera. From September 4, 2018, (date of the first reported cases) through March 12, 2019, a total of 10,730 cases and 69 (0.64%) deaths were reported nationally from nine of Zimbabwe’s 10 provinces (Figure). Most cases (94%) were reported from Harare Province, the country’s largest province, with a population of approximately 2 million. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 18, 2025
- Content source:
- Powered by CDC PHGKB Infrastructure